| Name | alogliptin |
|---|---|
| Synonyms |
Alogliptin Base
ALOGLIPTIN(ALOGLIPTINE, ALOGLIPTINA) Trelagllptin Impurity 2 ALOGLIPTIN(ALOGLIPTINE (R)-2-[6-(3-amino-piperidin-1-yl)-3-Methyl-2,4-dioxo-3,4-dihydropyriMidin-1(2H)-yl)Methyl]-benzonitrile Benzonitrile, 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-Methyl-2,4-dioxo-1(2H)-pyriMidinyl]Methyl] Alogliptin(free base) Alogliptin 13C6 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrile alogliptina ALOGLIPTINA Alogliptin(850-5) Axagliptin hydrate Alogliptin effective and selective DPP-4 inhibitor ALOGLIPTINE Trelagliptin Impurity T Unii-jhc049lo86 UNII-JHC049LO86 Alogliptin Intermediate 2-({6-[(3R)-3-Amino-1-piperidinyl]-3-methyl-2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl}methyl)benzonitrile ALOGLIPTIN(ALOGLIPTINE,ALOGLIPTINA) Alogliptin Benzoate API Alogliptin (SYR-322) Trelagliptin-11 AlogliptinQ: What is Alogliptin Q: What is the CAS Number of Alogliptin Q: What is the storage condition of Alogliptin Q: What e the applications of Alogliptin Troxagliptin impurities141 Trajenta Troxagliptin impuritiesT Agelieting 2-[[6-[(3R)-3-Amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]benzonitrile ALOGLIPTIN(ALOGLIPTINE, ALOGLIPTINA)###850-5 Trelagliptin Impurity 2(Alogliptin) ogL 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl}methyl)benzonitrile Alogliptin, 10 mM in DMSO Alogliptin 2-[[6-[(3R)-3-Amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]benzonitrile (R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitri |
| Description | Alogliptin(SYR-322) is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9.IC50 value: <10 nMTarget: DPP4Alogliptin is an orally administered, anti-diabetic drug in the DPP-4 inhibitor class. A randomized clinical trial reporting in 2011 aimed to determine the efficacy and safety of alogliptin versus placebo and voglibose among newly diagnosed Type 2 diabetes patients in Japan. The main outcome indicated that alogliptin was statistically superior to both comparitors. A randomized clinical trial reporting in 2012 aimed to demonstrate that alogliptin was "non-inferior" to a "very low fat/calorie traditional Japanese diet" among newly diagnosed Type 2 diabetes patients in Japan. The outcome indicated that both the drug and dietary treatments comparably impacted indicators of the diabetic condition, such as HbA1c levels and glycemic efficacy. The drug treatment had its impact without changing body mass index (BMI), but the dietary treatment was accompanied by a significant reduction in the BMI… |
|---|---|
| Related Catalog | |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 519.2±60.0 °C at 760 mmHg |
| Molecular Formula | C18H21N5O2 |
| Molecular Weight | 339.392 |
| Flash Point | 267.8±32.9 °C |
| Exact Mass | 339.169525 |
| PSA | 97.05000 |
| LogP | 1.84 |
| Vapour Pressure | 0.0±1.4 mmHg at 25°C |
| Index of Refraction | 1.660 |
|
~%
850649-61-5 |
| Literature: Journal of Medicinal Chemistry, , vol. 50, # 10 p. 2297 - 2300 |
|
~%
850649-61-5 |
| Literature: Journal of Medicinal Chemistry, , vol. 50, # 10 p. 2297 - 2300 |